AIM ImmunoTech CEO to Present at Webull Corporate Connect Webinar
Event summary
- AIM ImmunoTech Inc. will present in the Webull Corporate Connect Webinar Series on June 24, 2026.
- CEO Thomas Equels will deliver the presentation from 2:40 – 3:00 PM ET.
- Webull serves over 27 million registered users globally across 16 markets.
- AIM ImmunoTech focuses on Ampligen® (rintatolimod) for late-stage pancreatic cancer treatment.
The big picture
AIM ImmunoTech’s participation in Webull’s webinar series underscores its strategy to engage with a broader investor audience, particularly retail investors. The move aligns with trends in biotech companies leveraging digital platforms for outreach and transparency. With Ampligen® targeting a critical unmet need in pancreatic cancer, AIM’s ability to communicate its progress effectively could influence market perception.
What we're watching
- Investor Engagement
- How AIM ImmunoTech leverages Webull’s platform to expand its investor base and visibility among retail investors.
- Clinical Development
- Whether the presentation will provide updates on Ampligen®’s clinical trials or regulatory progress.
- Market Positioning
- The pace at which AIM ImmunoTech can differentiate itself in the competitive immuno-oncology space.